The Bill 118 hr 5539, also known as the ORPHAN Cures Act, is a piece of legislation introduced in the US Congress with the aim of addressing the needs of individuals with rare diseases, also known as orphan diseases. The bill seeks to improve access to treatments and cures for these diseases by providing funding for research and development of orphan drugs.
Specifically, the ORPHAN Cures Act aims to streamline the drug approval process for orphan drugs, which are medications designed to treat rare diseases that affect a small number of individuals. The bill also seeks to incentivize pharmaceutical companies to develop orphan drugs by providing tax credits and other financial incentives.
Additionally, the ORPHAN Cures Act includes provisions to improve coordination between government agencies, healthcare providers, and patient advocacy groups in order to better support individuals with rare diseases. The bill also calls for increased funding for research into orphan diseases and for the establishment of a national registry to track the prevalence of these conditions.
Overall, the ORPHAN Cures Act is a comprehensive piece of legislation aimed at improving access to treatments and cures for individuals with rare diseases. It seeks to address the unique challenges faced by individuals with orphan diseases and to promote innovation in the development of new therapies.